Source: Schoofs, G., et al. A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4. J. Vis. Exp. (2018).
In this video, we describe a flow cytometry-based competitive binding assay to detect the interactions between the CXC Chemokine Receptor 4 (CXCR4) and its fluorescently-labeled natural ligand CXC Chemokine Ligand 12 (CXCL12), in the presence of a CXCR4-targeting small molecule. Incubating CXCR4-expressing cells with lower small molecule concentrations allows CXCR4-CXCL12 binding to some extent, which progressively declines upon a gradual increase in small molecule concentrations.
1. Preparation of CXCL12, Assay Buffer, and Jurkat Cells for the Competition Binding Assay
2. Competition Binding Assay
NOTE: The actual competition binding assay is performed at RT and can be performed under non-sterile conditions.
3. Analysis of the samples by flow cytometry
CXCL12AF647 stained and fixated cells are now ready to be analyzed using flow cytometry. Several types of flow cytometers can be used, but they need to be equipped with the correct laser (i.e., a red laser, excitation range ~630 nm) for excitation and suitable filters for fluorophore detection (emission filters ~660 nm). They need to be capable of handling samples in a 96-well plate format. Examples of suitable flow cytometry devices are given in the Table of Materials and Reagents.
Figure 1: Overview of the workflow and illustration of the type of data obtained. (A). The main steps of the protocol are schematized for the negative and positive control samples, and compound-treated samples. Samples without compound pre-incubation and without addition of fluorescently labeled chemokine (CXCL12AF647) are included to determine the background (auto)fluorescence (negative control samples). Samples without compound pre-incubation, but with addition of a fixed amount of CXCL12AF647 are used to determine the maximal binding signal in the assay (positive control samples). In compound-treated samples, cells are pre-incubated with compound before addition of a fixed amount of CXCL12AF647. (B). The mean fluorescent binding signal is determined by flow cytometry analysis of Jurkat cells. From all events (i.e., Jurkat cells) analyzed (left panel) only the fluorescent signal from a gated subpopulation of cells is used for further analysis (middle panel). Pre-incubation of cells with small molecules (e.g., AMD3100) inhibits the binding of the fluorescently labeled receptor ligand and this will reduce the maximal binding signal (right panel, shown in a histogram representation). (C). A possible plate layout when performing the competitive binding assay in a 96-well plate format. In this case, six different compounds (cpd 1- 6) are tested in a 1/5 serial dilution series (in duplicate) ranging from 1,000 nM down to 0.32 nM.
The authors have nothing to disclose.
BD FACSCanto II | Becton Dickinson | Not applicable | Flow cytometry device |
BD FACSDIVA Software | |||
BD FACSArray | Becton Dickinson | Not applicable | Flow cytometry device |
BD FACSArray System Software | |||
Rapid flow filter: 0.2 μm aPES | Thermo Scientific | 566-0020 | |
FlowJo | FlowJo is now a wholly owned subsidiary of BD. | ||
Vi-CELL | Beckman Coulter | Not applicable | Cell viability analyzer |
Sigma 3-18 KS | Sigma | Not applicable | Centrifuge |
AMD3100 | Sigma | A5602-5mg | Specific CXCR4 antagonist |
h-SDF1a (AF647) | ALMAC | CAF-11-B-01 | Fluorescently-labeled CXCL12, CXCL12AF647 |
Sterilin microtiter plate, 96-well, U bottom, clear |
Thermo Scientific | 611U96 | |
Bovine Serum Albumin (BSA) | Sigma | A1933-25G | |
HBSS (10x), calcium, magnesium, no phenol red | Gibco (Life Technologies) | 14065-049 | |
HEPES (1M) | Gibco (Life Technologies) | 15630-056 | |
Dulbecco's Phosphate Buffered Saline (DPBS) | Gibco (Life Technologies) | 14190-094 | |
Jurkat cells | ATCC | ||
Reagent reservoir PP | Sigma | BR703411 | |
Falcon tubes, 50ml | Greiner Bio-One | 227 261 |